If youre injecting Wegovy for the first time, you can pick any of the three recommended locations (upper thigh, upper arm, or abdomen)
Strategy does
Check Out Our 5 Star Reviews Additional Services You May Need Injectables Laser Hair Removal HydraFacial Perfect Derma Peels Skin Pen Microneedling IPL Light Therapy (Photofacial) Spider Vein Facials Botox Kybella PRP Hair Restoration Semaglutide GLP-1 Vitamin B12 Shots Lip Filler Jeuveau Tirzepatide + B12 Neurotoxins SkinPen Microneedling with PRP Medical Grade Skincare Additional Services You May Need Injectables Laser Hair Removal HydraFacial Perfect Derma Peels Skin Pen Microneedling IPL Light Therapy (Photofacial) Spider Vein Facials Botox Kybella PRP Hair Restoration Semaglutide GLP-1 Vitamin B12 Shots Lip Filler Jeuveau Tirzepatide + B12 Neurotoxins SkinPen Microneedling with PRP Medical Grade Skincare
When patients lose significant weight on incretin-based therapiesoften 10-15% or more of initial body weight in clinical trials such as the STEP program (semaglutide) and SURMOUNT trials (tirzepatide)the reduction in subcutaneous fat decreases the body's natural insulation layer, making environmental temperatures feel colder than before
you can also search for UK trials via NIHR Be Part of Research (www.bepartofresearch.nihr.ac.uk) Do not discontinue any existing prescribed medication (such as semaglutide or tirzepatide) in anticipation of retatrutide becoming available For clinicians: Familiarise yourself with the LY3437943 development code and ongoing Phase 3 trial data, as patients may present with questions informed by media coverage Be prepared to discuss the distinction between investigational and approved therapies , and the importance of evidence-based prescribing Monitor MHRA and NICE communications for updates on regulatory submissions and technology appraisals From a safety perspective, the adverse effect profile observed in Phase 2 trials (as reported in the 2023 New England Journal of Medicine publication) was broadly consistent with other GLP-1-based therapies, with nausea, vomiting, diarrhoea, and decreased appetite being the most commonly reported side effects
Hypertension 60 , 833841 (2012)
